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ORIGINS OF THE ANNALS OF PHARMACOTHERAPY AND A TRIBUTE TO ITS FOUNDER
Donald C. McLeod I WOULD LIKE TO WELCOME YOU to the 25th Anniversary Meeting and Dinner of The Annals ofPharmacotherapy. This occasion is to honor those of you who do much hard, creative work for the journal. We have invited all of the people who serve as editorial board members, column editors, and those who serve as abstractors in the French and Spanish languages for the journal. My comments tonight concern the legacy of Donald E. Francke, the founder of the journal, and the evolution of the journal.
Francke got his start at the University of Michigan more than 50 years ago. He trained under Harvey Whitney, Sr., who was an early hospital pharmacy pioneer, and the person most credited with forming the American Society of Hospital Pharmacists (ASHP). In 1938, Francke was a resident at the University of Michigan Hospitals under Whitney, and was among the first residents (then called pharmacy interns) in the country. Francke was a builder of the American Society of Hospital Pharmacists. He did a number of things that are quite noteworthy. He wrote, with the help of his residents, what became the American Hospital Formulary Service, which began as the formulary of the University of Michigan Hospitals. Francke was the first editor of the American Journal ofHospital Pharmacy and he created credibility for that journal. He also developed the International Pharmaceutical Abstracts. He was one of the founding members of the Drug Information Associ- should be remembered as a great advocate and leader in the advancement of clinical pharmacy and, even 13 years after his death, we are all indebted to him.
The journal has undergone significant evolution since its inception. You can look at the early issues and see how the idea of the drug information center was formed. The articles were totally administrative and philosophic; not really the kind of information that we now recognize as real-ly tough drug information analysis and clinical problems. But the concept was there, and practice was changing dramatically in the mid-1960s when Drug Intelligence was created. Francke promoted the ideas of drug iv administrative services and compatibility and published a series of articles in the early years of the journal that resulted in a handbook of iv therapy and compatibility. This was very creative; none of the professional organizations were even talking about it. In those early years, he published a series of articles by Edward A. Hartshorn, Ph.D., on drug interactions. This was a pioneering event, and resulted in drug interactions being a major focus of practice for clinical pharmacy.
Francke published a series of articles by John G. Wagner, Ph.D., on clinical pharmacokinetics, which later were combined and published as a textbook. These articles presented the subject of pharmacokinetics to the profession in a novel and advanced way. Pharmacokinetic theory was not in the curriculum in most schools of pharmacy at that time. So, getting Wagner to do this was another major feat on the part of Francke. I can remember talking to him myself about publishing ideas. He was very relaxed, and would say, "Well, go ahead and do it." He let Hartshorn, Wagner, and a number of other people do what they wanted to do, and it advanced the cause, advanced what we were doing tremendously. In the 1960s, the first experiences of clinical pharmacy role models started appearing in Dlep, which would seem embarrassingly simple now. I remember Andy Canada writing an article in the journal on "The Pharmacist's Role in Drug Surveillance." He approached this philosophically in terms of how you go about doing it, and gave a few examples. The journal is now a leader in describing adverse drug events.
In the 1970s a clinical content shift began in the journal, again a reflection of clinical pharmacists' capabilities, desires, energies, and production. The journal is a reflection of clinical pharmacists and can never be more than the people who subscribe to and support it. So, in the 1970s, the articles became more scientific and creative. We started seeing case reports on drug interactions, occasionally more than just one case, and small studies done recording interactions. We saw clinical pharmacokinetics articles. Francke published a very innovative series of editorials analyzing problems of clinical pharmacy and academia, as clinical pharmacy was a new discipline, unsupported by many of the faculty with Ph.D. degrees, and was misunderstood or not understood by many of the deans. Francke developed this series in a very systematic, clear way, and laid out what the challenges were. We began to see articles that were a critical appraisal of drugs-not a description of drug information centers, but a real analysis. These articles reviewed new drugs and compared them with others in the class, defining the problems in pharmacokinetic data, things that were not known, not studied, what ought to be studied, and how to properly begin applying this drug to human conditions. We began to see articles on clinical pharmacy practice in medical specialty and subspecialty areas with more sophistication, describing the therapeutic input rather than providing only philosophic general ideas on proper drug use.
In 1978, Francke died and Harvey Whitney Jr. took over as editor. In the 1980s we saw a quantum leap in the therapeutic content of the journal. It continues to mirror the practitioners of our profession. We've seen the creation of pharmaceutical scientists, and I think we now have hundreds of clinical pharmacists who can be accurately described as pharmacotherapists, and who are full and respected advisers to physicians. Pharmacotherapists provide great services regarding human therapeutics, drug safety, and appropriate use of drugs. Once again this is reflected in the journal's content. We've seen the journal evolve from being a general pharmacy publication with a clinical plan to a pharmacotherapy journal. We've seen an expansion of clinical research. Articles on pharmacokinetics, pharmacodynamics, clinical trials, pharmacoepidemiology, and pharmacoeconomics reflect the great increase of sophistication of our pharmacy and medical colleagues. Throughout this time, there have been some proponents of a journal devoted solely to clinical research, and I agree that this is a needed strong signal of the maturation of the discipline and specialty. But we also need a journal that has the commentaries, reflections, and editorials that are not in total agreement with the deans or the faculties, or specific pharmaceutical groups. Our journal has served that role for a long time and we intend to continue to serve that role.
In summary, Harvey, The Annals staff, and I thank each of you for the worldwide success and professional influence of The Annals. You are carrying on the great traditions of liberal thought and hard science so effectively begun by Don Francke. You do this cheerfully and without pay. You do this independently without the backing of a professional organization. Of note, you do this without committees. Your influence is that of the written power of persuasion. If you have a good idea, Harvey and I will try to remember Francke's simple but powerful philosophy and say, "Do it."
